
    
      After being informed of the study and potential risks and benefits, patients meeting
      eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as
      follows:

      Inpatients:

        -  N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until
           discharge

        -  N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge

      Outpatients:

      - N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks
    
  